Skip to main content

Advertisement

SpringerLink
Log in

Dalbavancin in clinical practice: a particular place for the elderly?

  • Brief Report
  • Published:
European Journal of Clinical Microbiology & Infectious Diseases Aims and scope Submit manuscript

Abstract

We investigate dalbavancin efficiency and tolerance among elderly in Grenoble-Alpes 32 university hospital. Among the 65 patients who received dalbavancin, 51% (33) were considered as old. Patients presented mainly bones and joint infections (52%), surgical site infection 34 (31%), and infective endocarditis (IE) (8%). Clinical cure was confirmed for 79% of old 35 patients at 1, 3, and 6 months. Six adverse events (9%) were reported after 36 dalbavancin’s administration, but each time in combination with other antibiotics. 37 Dalbavancin had a significant effectiveness and safety profile and represents a real 38 therapeutic option in the management of deep and complex infections of elderly patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Data availability

The data of this study are available by contacting the corresponding authors upon reasonable request.

Code availability

Not applicable.

References

  1. Dunne MW, Puttagunta S, Sprenger CR, Rubino C, Van Wart S, Baldassarre J (2015) Extended-duration dosing and distribution of dalbavancin into bone and articular tissue. Antimicrob Agents Chemother 59(4):1849–1855

    Article  CAS  Google Scholar 

  2. Leuthner K, Buechler K, Kogan D, Saguros A, Lee S (2016) Clinical efficacy of dalbavancin for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Ther Clin Risk Manag 931–40. https://doi.org/10.2147/TCRM.S86330

  3. Knafl D, Tobudic S, Cheng SC, Bellamy DR, Thalhammer F (2017) Dalbavancin reduces biofilms of methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-resistant Staphylococcus epidermidis (MRSE). Eur J Clin Microbiol Infect Dis. 36(4):677–80

    Article  CAS  Google Scholar 

  4. Pfaller MA, Flamm RK, Castanheira M, Sader HS, Mendes RE (2018) Dalbavancin in-vitro activity obtained against Gram-positive clinical isolates causing bone and joint infections in US and European hospitals (2011–2016). Int J Antimicrob Agents avr 51(4):608–611

    Article  CAS  Google Scholar 

  5. US Food and Drug Administration (FDA). DALVANCETM highlights of prescribing information. Reference ID: 4296015

  6. McCurdy SP, Jones RN, Mendes RE, Puttagunta S, Dunne MW (2015) In vitro activity of dalbavancin against drug-resistant Staphylococcus aureus isolates from a global surveillance program. Antimicrob Agents Chemother août 59(8):5007–5009

    Article  CAS  Google Scholar 

  7. Bouza E, Valerio M, Soriano A, Morata L, Carus EG, Rodríguez-González C et al (2018) Dalbavancin in the treatment of different gram-positive infections: a real-life experience. Int J Antimicrob Agents avr 51(4):571–577

    Article  CAS  Google Scholar 

  8. Arena F, Romanini E, Rosi E, Salomone C, Tucci G, Pempinello C et al (2018) The role of dalbavancin in the multi-disciplinary management of wound infections in orthopaedic surgery. J Chemother 30(3):131–9

    Article  CAS  Google Scholar 

  9. Dunne MW, Talbot GH, Boucher HW, Wilcox M, Puttagunta S (2016) Safety of dalbavancin in the treatment of skin and skin structure infections: a pooled analysis of randomized, comparative studies. Drug Saf févr 39(2):147–157

    Article  CAS  Google Scholar 

  10. Dinh A, Duran C, Pavese P, Khatchatourian L, Monnin B, Bleibtreu A et al (2019) French national cohort of first use of dalbavancin: a high proportion of off-label use. Int J Antimicrob Agents 54(5):668–672

    Article  CAS  Google Scholar 

  11. Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C et al (2018) Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the general hospital of Vienna. Clin Infect Dis 67(5):795–8

    Article  CAS  Google Scholar 

  12. Salvi F, Miller MD, Grilli A, Giorgi R, Towers AL, Morichi V et al (2008) A manual of guidelines to score the modified Cumulative Illness Rating Scale and its validation in acute hospitalized elderly patients: validation of modified CIRS guidelines. J Am Geriatr Soc 56(10):1926–1931

    Article  Google Scholar 

  13. Comité de l’Antibiogramme de la Société Française de Microbiologie (CA- SFM); European Committee on Antimicrobial Susceptibility Testing (EUCAST). Recommandations [in French]

Download references

Author information

Authors and Affiliations

  1. Infectious Diseases Department, CH Alpes Léman, Contamine-sur-Arve, France

    Chloé Wackenheim

  2. Infectious Diseases Department, CHU de Grenoble Alpes, Grenoble, France

    Marion Le Maréchal, Myriam Blanc & Patricia Pavese

  3. Groupe de Recherche en Infectiologie Clinique (GRIC), CIC, CHU Grenoble Alpes, Grenoble, France

    Marion Le Maréchal, Gaëtan Gavazzi, Yvan Caspar & Patricia Pavese

  4. Pharmacy Department, CHU de Grenoble Alpes, Grenoble, France

    Hélène Pluchart

  5. Geriatric Medicine Department, CHU de Grenoble Alpes, Grenoble, France

    Gaëtan Gavazzi

  6. Bacteriology Laboratory, Institute of Biology and Pathology, CHU de Grenoble Alpes, Grenoble, France

    Yvan Caspar

Authors
  1. Chloé Wackenheim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marion Le Maréchal
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hélène Pluchart
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gaëtan Gavazzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Myriam Blanc
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yvan Caspar
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Patricia Pavese
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

GRIC

Corresponding authors

Correspondence to Chloé Wackenheim, Marion Le Maréchal, Hélène Pluchart, Gaëtan Gavazzi, Myriam Blanc, Yvan Caspar or Patricia Pavese.

Ethics declarations

Ethics approval

The research was conducted in accordance with the Declaration of Helsinki as well as national and institutional standards.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wackenheim, C., Le Maréchal, M., Pluchart, H. et al. Dalbavancin in clinical practice: a particular place for the elderly?. Eur J Clin Microbiol Infect Dis 41, 977–979 (2022). https://doi.org/10.1007/s10096-022-04427-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10096-022-04427-2

Keywords

Search

Navigation